# Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Qing Zhou,Chong‐Rui Xu,Ying Cheng,Yunpeng Liu,Gongyan Chen,Jiuwei Cui,Nong Yang,Yong Song,Xiaoling Li,Shun Lü,Jianying Zhou,Zhiyong Ma,Shiying Yu,Cheng Huang,Yongqian Shu,Zhen Wang,Jin‐Ji Yang,Hai‐Yan Tu,Wen‐Zhao Zhong,Yi‐Long Wu |
| Citations | 231 |
| DOI | 10.1016/j.ccell.2021.07.005 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3191778845 |
| PMID | 34388377 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Qing Zhou](https://scholariq.org/researchers/qing-zhou/)
- [Nong Yang](https://scholariq.org/researchers/nong-yang/)
- [Wen‐Zhao Zhong](https://scholariq.org/researchers/wen-zhao-zhong/)
- [Jin‐Ji Yang](https://scholariq.org/researchers/jin-ji-yang/)
- [Chong‐Rui Xu](https://scholariq.org/researchers/chong-rui-xu/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.